Therapeutic Asset Ratings
18,176 results matching 1 filter
91,564 assets · 7,904 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Cyclophosphamide
Mature T-Cell And NK-Cell Non-Hodgkin Lymphoma
City of Hope Medical Center
P2
BB
(70)
Cyclophosphamide
Head And Neck Carcinoma
National Cancer Institute (NCI)
P2
BB
(70)
Cyclophosphamide
Oropharyngeal Carcinoma
HRYZ Biotech Co.
P2
BB
(70)
Cyclophosphamide
Ovarian Serous Adenocarcinoma
Roswell Park Cancer Institute
P2
BB
(70)
Cyclophosphamide
Primary Effusion Lymphoma
National Cancer Institute (NCI)
P2
BB
(70)
Cyclophosphamide
Hairy Cell Leukemia
Kite, A Gilead Company
P2
BB
(70)
CYTARABINE
Acute Biphenotypic Leukemia
University of Washington
P2
BB
(70)
CYTARABINE
Follicular Lymphoma
Genmab
P2
BB
(70)
DOXORUBICIN
Primary Effusion Lymphoma
National Cancer Institute (NCI)
P2
BB
(70)
ETOPOSIDE
Nodal Marginal Zone B-Cell Lymphoma
University of California, Davis
P2
BB
(70)
Fludarabine
Anaplastic Large Cell Lymphoma
National Cancer Institute (NCI)
P2
BB
(70)
Fludarabine
Angioimmunoblastic T-Cell Lymphoma
National Cancer Institute (NCI)
P2
BB
(70)
Fludarabine
MALT Lymphoma
UNC Lineberger Comprehensive Cancer Center
P2
BB
(70)
Fludarabine
Nodal Marginal Zone B-Cell Lymphoma
UNC Lineberger Comprehensive Cancer Center
P2
BB
(70)
Fludarabine
Marginal Zone Lymphoma
Paolo Caimi, MD
P2
BB
(70)
Golcadomide
Diffuse Large B-Cell Lymphoma
Fondazione Italiana Linfomi - ETS
P2
BB
(70)
Irinotecan
Anaplastic Oligodendroglioma
City of Hope Medical Center
P2
BB
(70)
Irinotecan
Head And Neck Squamous Cell Carcinoma
Neonc Technologies, Inc.
P2
BB
(70)
LENALIDOMIDE
Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
P2
BB
(70)
LENALIDOMIDE
Mycosis Fungoides
City of Hope Medical Center
P2
BB
(70)
METHOTREXATE
Leukemia, Myeloid, Accelerated-Phase
University of Michigan Rogel Cancer Center
P2
BB
(70)
METHOTREXATE
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
University of Michigan Rogel Cancer Center
P2
BB
(70)
Nilotinib
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
The University of Hong Kong
P2
BB
(70)
Olaparib
Malignant Pancreatic Neoplasm
MOMA Therapeutics
P2
BB
(70)
Plerixafor
Hodgkins Lymphoma
Thomas Jefferson University
P2
BB
(70)
Showing 1251 to 1275 of 18,176 assets
Previous
Page 51 of 728
Next